Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10910923 | Lung Cancer | 2014 | 9 Pages |
Abstract
In the absence of direct head-to-head trial data comparing efficacy between the three EGFR TKIs, our analysis suggests that afatinib is a viable treatment alternative to erlotinib or gefitinib in terms of PFS. A direct trial-based comparison of the efficacy of these agents is warranted to clarify their relative benefits.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sanjay Popat, Tony Mok, James Chih-Hsin Yang, Yi-Long Wu, Juliane Lungershausen, Uz Stammberger, Ingolf Griebsch, Tiago Fonseca, Luis Paz-Ares,